SEC Filing Summary: Inhibrx Biosciences, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Inhibrx Biosciences, Inc. on February 23, 2026. The filing serves as a Regulation FD disclosure regarding the release of an updated corporate presentation to the investment community.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on the dissemination of a corporate presentation and does not contain audited financial statements or quarterly results.
Material Changes
No material financial changes versus prior periods are reported in this document. The primary event is the posting of an updated corporate presentation on the company's website under the "Investors" tab.
Guidance, Outlook, and Risks
The Company states it distributes the attached presentation to provide updates and summaries of its business. The filing explicitly notes that the Company undertakes no obligation to update, supplement, or amend the materials. The information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability and incorporation by reference.
Investor Verification Checklist
- Verify the content of the attached Exhibit 99.1 (Corporate Presentation) for specific business updates.
- Confirm the date of the presentation to ensure it reflects the most current data as of February 23, 2026.
- Review the company's website (www.inhibrx.com) under the "Investors" tab for the full presentation.
- Note that this 8-K does not contain financial data; refer to the most recent 10-K or 10-Q for financial metrics.